Introduction {#Sec1}
============

Type 2 diabetes mellitus is one of the major worldwide unresolved health challenges: it is a major risk factor for a number of common, sometimes potentially lethal diseases, such as hypertension, stroke, coronary heart disease^[@CR1]^, or kidney failure and retinopathy^[@CR2]^. According to the International Diabetes Federation, the worldwide prevalence of diabetes mellitus was 8.8% in 2015, and by 2040 the prevalence of diabetes in adults is predicted to rise to 10.4%^[@CR3]^. The increasing prevalence of obesity provides ground to the rising prevalence of type 2 diabetes^[@CR4]^. Even though the main cause of obesity is the imbalanced calorie intake, one intriguing hypothesis links the composition of the human gut microbiome to human energy homeostasis; for instance with their ability to promote adiposity through manipulation of host genes and metabolism, an altered microbiome can lead to predisposition to obesity^[@CR5]^. The alteration in the gut microbiota has recently been recognized as a key environmental factor resulting in metabolic diseases, such as type 2 diabetes. In fact, the gut microbiota is involved in the maintenance of host energy homeostasis and in the stimulation of host immunity through a molecular crosstalk^[@CR6]^.

Although many drugs have been developed to maintain glycemic control and normalize blood glucose levels either via enhanced insulin production and utilization, suppressed glucose production and absorption, by blocking urine glucose re-absorption and increasing glucose excretion in urine, or the combination of these^[@CR7]^, these drugs may cause several adverse effects such as sulphonylureas carry a risk of causing acute severe hypoglycemia; lactic acidosis is also a potentially serious adverse effect associated with the use of biguanides; and gastrointestinal adverse effects may occur with the use of metformin^[@CR8]^. Alternatively, the potential role of modifications in the gut microbiome had been explored as a new complementary therapeutic strategy^[@CR9]^. Clinical evidence supports the hypothesis that the modulation of the gut microbiota by probiotics could be effective in prevention and management of diabetes^[@CR10],[@CR11]^.

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. The healthy human body contains such microbes physiologically; and they can be obtained in forms of over-the-counter food supplements as well. Over the last few years, probiotics, especially the lactobacillus species were shown to be effective in the therapy of type 2 diabetes^[@CR12]^. In type 2 diabetes, gut microbiome is found to be different from that in the healthy population. In a human study, the amount of *Firmicutes* bacteria was lower, whereas the number of *Bacteroides* and *Proteobacteria* is higher in the gastrointestinal tract of patients with type 2 diabetes compared to non-diabetic persons^[@CR13]^. According to the study^[@CR13]^, the ratio of *Bacteriodes* and *Firmicutes* species had positive correlation with decreased insulin resistance, however, causality has not been proven yet. Following innovative dietary strategies, it seems possible to maintain euglycemia by normalizing the altered microbiome, and to prevent long-term micro- and macrovascular complications of type 2 diabetes^[@CR9]^. Although, there have been numerous bacterial species investigated in the therapy of type 2 diabetes, no consensus has been obtained regarding the effectivity and the most effective species. For instance, an earlier meta-analysis suggested, that the intake of certain *Lactobacillus* species, such as *L. fermentum, L. ingluviei* and *L. acidophilus* can lead to weight gain, while the ingestion of *L. gasseri* and *L. plantarum* might end up in weight loss both in animal and human studies^[@CR14]^. Previous meta-analysis in this field were not conducted with assessment of the evidence quality levels and the number of identified trials that met their inclusion criteria was relatively low (7--12 trials)^[@CR15]--[@CR19]^. Two meta-analysis found no significant effects of probiotics on lipid profile^[@CR16],[@CR19]^ and two meta-analysis found decreased indexes of lipid profiles^[@CR17],[@CR18]^. These contradictory reports on the effect of probiotics inspired us to conduct an updated meta-analysis to assess the effect of probiotic therapies in diabetes mellitus type 2 exclusively from randomized controlled trials.

Materials and methods {#Sec2}
=====================

Protocol and registration {#Sec3}
-------------------------

This meta-analysis was reported according to the recommendation of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines^[@CR20]^. Pre-specified protocol of this meta-analysis was published in the Prospero Center for Reviews and Dissemination (PROSPERO) under the registration number of CRD42019137997.

Search strategy {#Sec4}
---------------

Meta-analysis was performed using the PICO format: whether an intervention with probiotic supplementation (I) compared with placebo (C) has any effect on metabolic parameters (body mass index (BMI), total-cholesterol, low density lipoprotein (LDL), triglycerides (TG), high density lipoprotein (HDL), high sensitivity C-reactive protein (hs-CRP), haemoglobin A1c (HbA1c), fasting plasma glucose and insulin levels, systolic and diastolic blood pressure (SBP, DBP) (O) in patients with diabetes mellitus type 2 (P). In general, the following search terms were used in all databases: diabetes mellitus type 2 AND (probiotic\* OR lactobacillus OR saccharomyces OR enterococcus OR escherichia coli OR streptococcus OR bifidobacterium) AND random\*. Trials were identified by searching MEDLINE (via PubMed), EMBASE and CENTRAL databases up to 5th of April 2019. No filters or restrictions were applied. We included human trials without any restriction to language or year of publication.

Eligibility criteria and study selection {#Sec5}
----------------------------------------

Duplicates were removed by the EndNote software first automatically, then manually. Randomized controlled trials in which probiotics in the form of any pharmaceutical formulations or dairy products administered to adult patients with type 2 diabetes were included after title and abstract screening. Combination therapy was not an exclusion criterion. Subsequently, full texts of the articles were reviewed for inclusion of eligible studies. Two review authors (TK and BM) selected the articles fulfilling the inclusion criteria independently, and any disagreement was resolved by consensus.

Data collection {#Sec6}
---------------

At the end of the screening process, relevant data were independently extracted from studies by the two review authors and any disagreement was resolved by consensus. Data were extracted into a standardized excel sheet form. Data extracted from the papers included: number of participants, dosage, the intervention used, study duration and the outcome parameters including BMI changes as primary outcome and changes in the total-cholesterol, LDL, TG, HDL, hs-CRP, HbA1C, fasting plasma glucose and insulin levels, SBP and DBP as secondary outcomes. The authors of the studies and year of publication were also recorded. Mean values for control and intervention groups, along with the measure of dispersion were extracted.

Risk of bias assessment {#Sec7}
-----------------------

Two review authors assessed the risk of bias of the studies independently, and any disagreement was resolved by consensus. The assessment was performed using the updated version of the Cochrane risk-of-bias tool for randomized trials (RoB 2) with the following domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of the outcome, bias in selection of the reported result, and overall bias^[@CR21]^.

Quality of evidence {#Sec8}
-------------------

We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to rate the quality of evidence on our primary outcomes.

Statistical analysis {#Sec9}
--------------------

We calculated weighted mean differences (WMD) with 95% confidence intervals (CI) as effect size data based on the difference of before-after values in the intervention and comparator groups. Means were compared by assessing the overlap of CIs. Between-study heterogeneity was tested with (a) chi2 statistics (where *p* \< 0.1 was considered significant) and (b) I^2^ statistics, where 75--100% was considered considerable^[@CR22]^. Due to the methodological differences between interventions, we performed all analysis under the random effect assumption. To assess small study effect, we used visual inspection of funnel plots and Egger\'s test was performed. If *p* ≥ 0.1, publication bias is unlikely to occur in the sample. We used trial sequential analysis to investigate if alpha and beta-type errors affect our estimates. All analyses were performed with the Comprehensive Meta-analysis software (Biostat, Inc., Engelwood, MJ, USA) and Stata 11 SE (Stata Corp) software.

Results {#Sec10}
=======

Characteristics of the included studies {#Sec11}
---------------------------------------

A flow chart of selection for the meta-analysis is shown in Fig. [1](#Fig1){ref-type="fig"}.Figure 1A flow diagram detailing process of study selection for the meta-analysis.

32 eligible studies were included in the meta-analysis^[@CR12],[@CR23]--[@CR52]^. Main characteristics of the studies included are shown in Table [1](#Tab1){ref-type="table"}. Fifteen studies administered one bacterial species, while the rest of the studies used a combination of more than one strain: seventeen studies administered two to seven bacterial species. In one article, the flora of the probiotic yoghurt of the intervention group was enriched with specific strains, however placebo yoghurt also contained bacterial flora^[@CR12]^. In three articles, probiotics were co-administered with chromium^[@CR35],[@CR51],\ [@CR52]^, in one article with selenium^[@CR42]^, and in one article with vitamin D^[@CR43]^. The duration of intervention ranged from four to 34 weeks. Seventeen of the 32 articles were published from Iran, two from Saudi Arabia, two from Ukraine, two from Brazil, two from India, and the remaining ones from Malaysia, Denmark, Taiwan, Poland, Sweden, Japan, and Greek.Table 1Characteristics and findings of the studies included in the analysis.CountryTotal number of participantsType of participantsStrains usedDaily doseDuration of treatment (weeks)OutcomesAbbasi et al.^[@CR23]^Iran40T2DM (for: \> 1 year, FPG: \> 126 mg/dL, PPG: \> 200 mg/dL, microalbuminuria, GFR: \> 60 mL/min)*L. plantarum*2 × 10^7^ CFU/mL8BW, BMI, TC, TG, LDL-C, HDL-CAsemi et al.^24^Iran54T2DM (FPG: \> 126 mg/dL/PPG: \> 200 mg/dL/HbA1c: \> 6, 5%)*L. acidophilusL. caseiL. rhamnosusL. bulgaricusB. breveiB. longumStrep. thermophilus*2 × 10^9^ CFU7 × 10^9^ CFU1.5 × 10^9^ CFU2 × 10^8^ CFU2 × 10^10^ CFU7 × 10^9^ CFU1.5 × 10^9^ CFU8BW, BMI, TC, TG, LDL-C, HDL-C, CRP, HbA1c, FPG, InsulinBahmani et al.^25^Iran81T2DM (FPG: \> 126 mg/dL/PPG: \> 200 mg/dL/HbA1c: \> 6,5%)*L. sporogenes*3 × (40 × 10^8^ CFU)8BW, BMIBayat et al.^26^Iran80T2DM (FPG: \> 126 mg/dL and controlled lipid profile w/o changing the drug instruction)*Not specified, probiotic yoghurt*Not known8TC, TG, LDL-C, HDL-C, CRP, HbA1c, FPGEjtahed et al.^12^Iran60T2DM (for: \> 1 year and BMI: \< 35 and LDL-C: \> 2.6 mmol/L )*L. acidophilusB. lactisL. bulgaricusStrep. thermophilus*300 × (1.05 × 10^6^ CFU)300 × (1,19 × 10^6^ CFU)Not knownNot known6TC, TG, LDL-C, HDL-CFeizzollahzadeh et al.^[@CR27]^Iran40T2DM*L. plantarum*2 × 10^7^ CFU8TG, LDL-C, HDL-C, CRP, FPGFirouzi et al.^[@CR28]^Malaysia136T2DM (for: \> 0.5 year, HbA1c: 6.5--12%, FPG: \< 15 mmol/L, BMI: 18.5--40)*L. acidophilusL. caseiL. lactisB. bifidumB. longumB. infantis*10^10^ CFU10^10^ CFU10^10^ CFU10^10^ CFU10^10^ CFU10^10^ CFU12BW, BMI, TC, TG, LDL, HDL, CRP, HbA1c, FPG, Insulin, SBP, DBPHariri et al.^[@CR29]^Iran40T2DM (for: \> 1 year, FPG: \> 126 mg/dL, PPG: \> 200 mg/dL)*L. plantarum*200 × (2 × 10^7^ CFU)8BW, BMI, SBP, DBPHove et al.^[@CR30]^Denmark41T2DM (for: \> 1 year, HbA1c: 6--10%)*L. helveticus*300 mL12BW, BMI, TC, TG, LDL-C, HDL-C, CRP, HbA1c, FPGHsieh et al.^[@CR31]^Taiwan68T2DM (for: 0.5 years, BMI: \> 18, HbA1c: 7--10%)*L. routeri (live)L. routeri (heat killed)*2 × (2 × 10^9^ CFU)2 × (1 × 10^10^ CFU)12TC, TG, LDL-C, HDL-C, HbA1c, Insulin, SBP, DBPKhalili et al.^[@CR32]^Iran40T2DM (for: \> 1 years, BMI: \< 35)*L. casei*10^8^ CFU8BW, BMI, HbA1c, FPG, Insulin, SBP, DBPKobyliak et al.^[@CR33]^Ukraine58T2DM (BMI: \> 25, NAFLD)*Lactococcus, Bifidobacterium, Propionibacterium, Acetobacter*10 × (6 × 10^10^ CFU)10 × (1 × 10^10^ CFU)10 × (3 × 10^10^ CFU)10 × (3 × 10^6^ CFU)8TC, TG, LDL-C, HDL-CKobyliak et al.^[@CR34]^Ukraine53T2DM (for: 0.5 years, BMI: \> 25, HbA1c: 6.5--11%, HOMA-IR: \> 2)*Lactococcus, Bifidobacterium, Propionibacterium, Acetobacter*10 × (6 × 10^10^ CFU)10 × (1 × 10^10^ CFU)10 × (3 × 10^10^ CFU)10 × (3 × 10^6^ CFU)8BW, BMI, HbA1c, FPG, InulinKról et al.^[@CR35]^Poland20T2DM (BMI: 35.3 (9.2), HbA1c: \> 7.0%)*Saccharomyces cerevisiae*5 × 100 μg8BMI, TC, TG, LDL-C, HDL-C, HbA1c, FPG, InsulinMafi et al.^[@CR36]^Iran60T2DM with diabetic nephropathy (Proteinuria: \> 0.3 g/day)*L. acidophilusL. reuteriL. phermentumB. bifidum*2 × 10^9^ CFU2 × 10^9^ CFU2 × 10^9^ CFU2 × 10^9^ CFU12BW, BMI, TC, TG, LDL-C, HDL-C, CRP, HbA1c, FPG, InsulinMazloom et al.^[@CR37]^Iran34T2DM (for: \< 15 years, FPG: \> 126 mg/dL)*L. acidophilusL. bulgaricusL, bifidumL. casei*Not known6TC, TG, LDL-C, HDL-C, CRP, FPGMobini et al.^[@CR38]^Sweden44T2DM (for: \> 0.5 years, waist: \> 80 cm \[F\] or \> 94 cm \[M\], HbA1c: 6.7--10.4%, BMI: 25--45)*L. reuteriL. reuteri*10^8^ CFU10^10^ CFU12BW, BMI, TC, TG, LDL-C, HDL-C, CRP, HbA1c, FPG, SBP, DBPMohamadshai et al.^[@CR39]^Iran44T2DM (BMI: \> 25)*L. bulgaricusStrep. thermophilusB. lactisL. acidophilus*Not knownNot known300 × (3,7 × 10^6^ CFU)300 × (3,7 × 10^6^ CFU)8BW, BMI, CRP, HbA1c, FPGMoroti et al.^[@CR40]^Brazil20T2DM (TC: \> 200 mg/dL, TG: \> 150 mg/dL, FPG: \> 110 mg/dL)*L. acidophilusB. bifidum*200 × (1 × 10^8^ CFU)200 × (1 × 10^8^ CFU)4,3TC, TG, HDL-C, FPGOstadrahimi et al.^[@CR41]^Iran60T2DM (for: \< 20 years, FPG: \> 125 mg/dL)*Strep. thermophilesL. caseiL. acidophilusB. lactis*Not known1,200 × (15 × 10^6^ CFU)1,200 × (25 × 10^6^ CFU)1,200 × (8 × 10^6^ CFU)8BW, TC, TG, LDL-C, HDL-C, HbA1c, FPGRaygan et al.^[@CR42]^Iran54T2DM w/ 2- or 3-vessel CHD*L. acidophilusL. reuteriL. fermentumB. bifidum*2 × 10^9^ CFU/g2 × 10^9^ CFU/g2 × 10^9^ CFU/g2 × 10^9^ CFU/g12BW, BMI, TC, TG, LDL-C, HDL-C, CRP, FPG, Insulin, SBP, DBPRaygan et al.^[@CR43]^Iran60T2DM w/ 2- or 3-vessel CHD*L. acidophilusL. reuteriL. fermentumB. bifidum*2 × 10^9^ CFU/g2 × 10^9^ CFU/g2 × 10^9^ CFU/g2 × 10^9^ CFU/g12BW, BMI, TC, TG, LDL-C, HDL-C, CRP, FPG, Insulin, SBP, DBPRaygan et al.^[@CR44]^Iran60T2DM w/ 2- or 3-vessel CHD*B. bifidumL. caseiL. acidophilus,*2 × 10^9^ CFU/g2 × 10^9^ CFU/g2 × 10^9^ CFU/g12BW, BMI, TC, TG, LDL-C, HDL-C, CRP, FPG, Insulin, SBP, DBPSabico et al.^[@CR45]^Saudi-Arabia78T2DM (for: \< 0.5-year, w/o complications, HbA1c: \< 7%)*B. bifidumB. lactisL. acidophilusL. brevisL. caseiL. salivariusLactococcus lactis W19Lactococcus lactis W58*2 × (2.5 × 10^9^ CFU/g)12BW, BMI, TC, TG, LDL-C, HDL-C, FPG, Insulin, SBP, DBPSabico et al.^[@CR45]^Saudi-Arabia61T2DM (for: \< 0.5-year, w/o complications, HbA1c: \< 7%)*B. bifidumB. lactisL. acidophilusL. brevisL. caseiL. salivariusLactococcus lactis W19Lactococcus lactis W58*2 × (2.5 × 10^9^ CFU/g)34,13BMI, TC, TG, LDL-C, HDL-C, CRP, FPG, Insulin, SBP, DBPSato et al.^[@CR46]^Japan68T2DM (HbA1c: 6--8%)*L. casei*4 × 10^10^ CFU16BMI, TC, TG, HDL-C, CRP, HbA1c, FPGShakeri et al.^[@CR47]^Iran52T2DM (FPG: \> 126 mg/dL/PPG: \> 200 mg/dL/HbA1c: \> 6,5%)*L. sporogenes*3 × (40 × 10^8^ CFU)8BW, BMI, TC, TG, LDL-C, HDL-C, FPG,Sharma et al.^[@CR48]^India40T2DM (newly onset)*Saccharomyces cerevisiae*9 g12BMI, TC, TG, LDL-C, HDL-C, HbA1c, FPG, SBP, DBPSheth et al.^[@CR49]^India35T2DM (pre-hypertensive)*LactobacillusBifidobacteriumStreptococcus*Not knownNot knownNot known6.43HbA1c, FPGTajadadi-Ebrahimi et al. 2014Iran71T2DM (FPG: \> 126 mg/dL/PPG: \> 200 mg/dL/HbA1c: \> 6.5%)*L. sporogenes,*3 × (40 × 10^8^ CFU)8BW, BMI, CRP, FPG, InsulinTonucci et al.^[@CR50]^Brazil55T2DM (for: \> 1 year, BMI: \< 35)*Strep thermophilusL. acidophilusB. lactis*Not known120 × 10^9^ CFU120 × 10^9^ CFU6TC, TG, LDL-C, HDL-C, HbA1c, FPG, InsulinYanni et al.^[@CR51]^Greece30T2DM (for: \> 1 year, BMI: \< 31, FPG: \> 125 mg/dL, HbA1c: \< 8.5%)*Saccharomyces cerevisiae*Not known12BW, BMI, TC, TG, HDL-C, CRP, HbA1c, FPG, Insulin, SBP, DBP*T2DM* type 2 diabetes mellitus, *FPG* fasting plasma glucose, *PPG* postprandial plasma glucose, *HbA1c* glycated hemoglobin, *GFR* glomerular filtration rate, *BW* body weight, *BMI* body mass index, *TC* total cholesterol, *TG* triglyceride, *LDL-C* low-density lipoprotein, *HDL-C* high-density lipoprotein, *CFU* colony forming unit, *CRP*C-reactive protein, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *L.*Lactobacillus, *B.* Bifidobacterium, *Strep.* Streptococcus, *NAFLD* non-alcoholic fatty liver disease, *CHD* coronary heart disease, *HOMA-IR* Homeostatic Model Assessment for Insulin Resistance.

Summary of findings {#Sec12}
-------------------

Data of outcome parameters are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Summary data of outcome parameters.NWMDCI lowCI high*p*I^2^ (%)p (I^2^)BMI (kg/m^2^)17− 0.17− 0.380.040.11486.6 \< 0.001T-chol (mg/dL)21− 10.06− 15.94− 4.18**0.001**93.2 \< 0.001LDL (mg/dL)20− 3.77− 8.470.930.11688.6 \< 0.001TG (mg/dL)21− 17.18− 26.17− 8.19** \< 0.001**34.00.065HDL (mg/dL)221.620.213.04** \< 0.001**57.4 \< 0.001CRP (mg/dL)16− 0.43− 0.8− 0.07**0.019**64.3 \< 0.001HbA1c (%)14− 0.33− 0.53− 0.13**0.001**75.9 \< 0.001FPG (mg/dL)24− 16.52− 23.28− 9.76** \< 0.001**66.2 \< 0.001Insulin (µIU/mL)15− 1.40− 2.52− 0.27**0.015**46.80.024SBP (mmHg)14− 1.79− 3.09− 0.49**0.007**0.00.89DBP (mmHg)14− 1.32− 2.42− 0.21**0.019**0.00.838Bold values indicate statistically significant weighted mean differences between the intervention and control groups, where *p* \< 0.05.*N* number of RCTs, *WMD* weighted mean difference, *CI* confidence interval, *BMI* body mass index, *T-chol* total cholesterol, *LDL* low-density lipoprotein, *TG* triglyceride, *HDL* high-density lipoprotein, *CRP* C-reactive protein, *HbA1c* hemoglobin A1c, *FPG* fasting plasma glucose, *SBP* systolic blood pressure, *DBP* diastolic blood pressure. The summary of findings table provides a synopsis of the analysis (Table [3](#Tab3){ref-type="table"}).Table 3Probiotics consumption compared to control in diabetes mellitus type 2.Certainty assessmentNo. of patientsEffectCertaintyImportance№ of studiesStudy designRisk of biasInconsistencyIndirectnessImprecisionOther considerationsProbioticsControlAbsolute (95% CI)**Body mass index**17Randomized trialsNot seriousSerious^a^Very serious^b^Serious ^c^None498497WMD 0.17 kg/m^2^ lower (0.38 lower to 0.04 higher)![](41598_2020_68440_Figa_HTML.gif){#d30e2525}Very lowImportant**Total cholestero**l21Randomized trialsNot seriousVery serious^a^Very serious^b^Not seriousNone596600WMD 10.06 mg/dL lower (15.94 lower to 4.18 lower)![](41598_2020_68440_Figa_HTML.gif){#d30e2578}Very lowImportant**LDL**20Randomized trialsNot seriousSerious^a^Very serious^b^Not seriousNone546544WMD 3.77 mg/dL lower (8.47 lower to 0.93 higher)![](41598_2020_68440_Figa_HTML.gif){#d30e2630}Very lowImportant**Triglyceride**21Randomized trialsNot seriousNot seriousVery serious^b^Not seriousNone546548WMD 17.18 mg/dL lower (26.17 lower to 8.19 lower)![](41598_2020_68440_Figb_HTML.gif){#d30e2680}LowImportant**HDL**22Randomized trialsNot seriousNot seriousVery serious^b^Serious ^d^None594598WMD 1.62 mg/dL higher(0.21 higher to 3.04 higher)![](41598_2020_68440_Figa_HTML.gif){#d30e2734}Very lowImportant**CRP**16Randomized trialsNot seriousSerious ^e^Very serious^b^Serious ^d^None467470WMD 0.43 mg/l lower (0.8 lower to 0.07 lower)![](41598_2020_68440_Figa_HTML.gif){#d30e2789}Very lowImportant**HbA1c**14Randomized trialsNot seriousSerious^a^Very serious^b^Not seriousNone395372WMD 0.33% lower (0.53 lower to 0.13 lower)![](41598_2020_68440_Figa_HTML.gif){#d30e2841}Very lowImportant**Fasting plasma glucose**24Randomized trialsNot seriousSERIOUS^a^Very serious^b^Not seriousNONE649627WMD 16.52 mg/dL lower (23.28 lower to 9.76 lower)![](41598_2020_68440_Figa_HTML.gif){#d30e2893}Very lowImportant**Fasting insulin**15Randomized trialsNot seriousNOT seriousVery serious^b^Not seriousNone455451WMD 1.4 µIU/mL lower (2.52 lower to 0.27 lower)![](41598_2020_68440_Figb_HTML.gif){#d30e2943}LowImportant**Systolic blood pressure**14Randomized trialsNot seriousNot seriousVery serious^b^Not seriousPublication bias strongly suspected ^f^417418WMD 1.79 Hgmm lower (3.09 lower to 0.49 lower)![](41598_2020_68440_Figa_HTML.gif){#d30e2995}Very lowImportant**Diastolic blood pressure**14Randomized trialsNot seriousNot seriousVery serious^b^Not seriousPublication bias strongly suspected ^f^417418WMD 1.32 Hgmm lower (2.42 lower to 0.21 lower)![](41598_2020_68440_Figa_HTML.gif){#d30e3047}Very lowImportant*CI* confidence interval.^a^Considerable heterogeneity was detected.^B^Differences between interventions were substantial.^c^Unusually high confidence interval in two of the studies.^d^Unusually high confidence interval in one of the studies.^e^Moderate heterogeneity was detected.^f^Egger\'s test was significant.

Risk of bias within the individual studies {#Sec13}
------------------------------------------

One study had high risk overall^[@CR40]^. In seven studies, some concerns were detected; however, we found no articles with any concern about missing outcome data. The quality of the included studies is shown in detail in Fig. [2](#Fig2){ref-type="fig"}. Generally, the quality of the studies was good, in most cases with published pre-study protocols. We found three studies that were single-blind^[@CR37],[@CR51],[@CR52]^, three more studies without blinding^[@CR26],[@CR46],[@CR48]^, all the other articles contained double-blind studies.Figure 2Risk of bias summary assessment of the included studies.

Probiotics did not change body mass index {#Sec14}
-----------------------------------------

Seventeen studies reported BMI changes. Pooled data showed no difference between the probiotic and placebo group. Considerable heterogeneity (I^2^: 86.6%, *p* \< 0.001) was detected.

Probiotics improved plasma lipid profile {#Sec15}
----------------------------------------

Twenty-one studies included data about the effect of probiotics on total-cholesterol level. Pooled data showed a significant effect of probiotics on reducing total-cholesterol levels with a mean difference of 10.06 mg/dL (95% CI − 15.94, − 4.18, *p* = 0.001) with a considerable heterogeneity (I^2^: 93.2%, *p* \< 0.001). Sub-group analysis according to the length of investigation (i.e. duration of treatment) did not reduce the heterogeneity (Fig. [3](#Fig3){ref-type="fig"}, short: I^2^: 93.2%, *p* \< 0.001; long: I^2^: 93.4%, *p* \< 0.001). Short studies with 8 weeks treatment or shorter showed significant decrease of total cholesterol level (− 14.56 mg/dL, 95% CI − 24.82, − 4.29, *p* = 0.005), while studies of 12 weeks or longer showed no significant change (*p* = 0.105).Figure 3Forest plot for the effect of probiotics on total cholesterol (T-chol) compared to controls in pooled analysis. The shaded diamonds indicate the effect of probiotics in a particular study (weighted difference in mean). The horizontal lines represent 95% confidence intervals (CIs). The big diamond data marker indicates the pooled effect. The figure shows the summary of studies overall and subdivided by length of intervention. "long": 12 weeks or longer, "short": 8 weeks or shorter.

We found a significant difference between these two sub-groups (*p* = 0.001). Sub-group analysis according to the number of bacterial strains (single or multiple, Fig. [4](#Fig4){ref-type="fig"}) did not change heterogeneity, either (multiple: I^2^: 91.5%, *p* \< 0.001, single: I^2^: 81.6%, *p* \< 0.001). The beneficial effect of multiple strains probiotics on total cholesterol was significant (− 11.70 mg/dL, 95% CI − 18.60, − 4.79, *p* = 0.001), however no difference was observed in single bacteria probiotic sub-group (*p* = 0.611) with significant difference between the two sub-groups (*p* \< 0.001).Figure 4Forest plot for the effect of probiotics on total cholesterol (T-chol) compared to controls in pooled analysis. The shaded diamonds indicate the effect of probiotics in a particular study (weighted difference in mean). The horizontal lines represent 95% confidence intervals (CIs). The big diamond data marker indicates the pooled effect. The figure shows the summary of studies overall and subdivided by the number of bacterial species used. "multiple": combination of bacteria, "single": one bacterial species used.

If we excluded the six articles where probiotics were co-supplemented with either vitamin D or chromium or selenium, and the article where the placebo group also got yoghurt with some bacteria, the heterogeneity did not change, nor the direction of the association (Figure [S1](#MOESM1){ref-type="media"}).

Twenty studies reported data about LDL levels. No significant difference in LDL levels was observed between probiotic and placebo users (− 3.77 mg/dL, 95% CI − 8.47, 0.93, *p* = 0.116) with a considerable heterogeneity (I^2^: 88.6%, *p* \< 0.001). Sub-group analysis according to the length of treatment (Figure [S2](#MOESM1){ref-type="media"}) did not decrease the heterogeneity (short: I^2^: 88.9%, *p* \< 0.001, long: I^2^: 89.5%, *p* \< 0.001). Pooled studies with 8 weeks treatment period or shorter (*p* = 0.167) and studies of 12 weeks or longer showed no change of total cholesterol level (*p* = 0.493). We found no significant difference between these two groups (*p* = 0.555). Sub-group analysis according to the number of bacteria used (single or multiple, Figure [S3](#MOESM1){ref-type="media"} did not change heterogeneity, either (multiple: I^2^: 90.6%, *p* \< 0.001, single: I^2^: 86.0%, *p* \< 0.001). We found no effect of multiple-strain probiotics on total cholesterol (*p* = 0.139), and no difference was observed in single bacterium containing probiotic sub-group (*p* = 0.985), while there was no difference between the two sub-groups (*p* = 0.119). If we excluded the six articles where probiotics were co-supplemented with either vitamin D or chromium or selenium, and the article where the placebo group also got yoghurt with some bacteria, heterogeneity did not change, either (Figure [S4](#MOESM1){ref-type="media"}). However, based on our trial sequential analysis, a number of 3,442 observations would be needed to provide sufficient statistical power (vs. the 1,090 patients in the current analysis) (Figure [S5](#MOESM1){ref-type="media"}).

The meta-analysis of twenty-one trials showed a significant reduction of triglyceride by 17.18 mg/dL (95% CI − 26.17, − 8.19, *p* \< 0.001). Heterogeneity was not substantial (34%, *p* = 0.065), sub-group analysis was therefore not conducted.

The meta-analysis of twenty-two trials showed a significant increase of HDL by 1.62 mg/dL (95% CI 0.21, 3.04, *p* = 0.025). I^2^ test (57.4%, *p* \< 0.001) may represent moderate heterogeneity due to the differences between the interventions.

Probiotics decreased CRP, HbA1c, fasting plasma glucose, fasting insulin, and blood pressure values {#Sec16}
---------------------------------------------------------------------------------------------------

The meta-analysis of sixteen trials showed a significant decrease of CRP by 0.43 mg/dL (95% CI − 0.80, − 0.07, *p* = 0.019). I^2^ test (64.3%, *p* \< 0.001) represented moderate heterogeneity.

Fourteen studies with reported the effect of probiotics on HbA1c levels. The decrease of HbA1c was slightly but significantly lower in the probiotic groups compared to placebo (− 0.33%, 95% CI − 0.53; − 0.13, *p* = 0.001). Heterogeneity was substantial (I^2^: 75.9%, *p* \< 0.001).

Twenty-four studies reported data about fasting plasma glucose. Pooled data showed a significant effect of probiotics in reducing fasting plasma glucose levels with a mean difference of − 16.52 mg/dL, (95% CI − 23.28; − 9.76, *p* \< 0.001) with a substantial heterogeneity (I^2^: 66.2%, *p* \< 0.001). Sub-group analysis according to the length of investigation (Fig. [5](#Fig5){ref-type="fig"}) did not change the heterogeneity in the long-term treatment sub-group (I^2^: 80.6, *p* \< 0.001), however it decreased significantly in the short period therapy sub-group (I^2^: 25.8%, *p* = 0.183).Figure 5Forest plot for the effect of probiotics on fasting plasma glucose (FPG) compared to controls in pooled analysis. The shaded diamonds indicate the effect of probiotics in a particular study (weighted difference in mean). The horizontal lines represent 95% confidence intervals (CIs). The big diamond data marker indicates the pooled effect. The figure shows the summary of studies overall and subdivided by length of intervention. "long": 12 weeks or longer, "short": 8 weeks or shorter.

Short studies with 8 weeks or shorter showed significant decrease of fasting plasma glucose level (− 15.35 mg/dL, 95% CI − 24.83, − 5.87, *p* = 0.002), and studies of 12 weeks or longer also showed a significant decrease (− 18.82 mg/dL, 95% CI − 28.58, − 9.06, *p* \< 0.001). We found no significant difference between these two sub-groups (*p* = 0.723). Sub-group analysis according to the number of applied bacteria strains (single or multiple, Fig. [6](#Fig6){ref-type="fig"}) showed an increased heterogeneity in the single strain sub-group, and there was some minor decrease in the multiple strains sub-group (single: I^2^: 74.5%, *p* \< 0.001; multiple: I^2^: 60.6%, *p* \< 0.001).Figure 6Forest plot for the effect of probiotics on fasting plasma glucose (FPG) compared to controls in pooled analysis. The shaded diamonds indicate the effect of probiotics in a particular study (weighted difference in mean). The horizontal lines represent 95% confidence intervals (CIs). The big diamond data marker indicates the pooled effect. The figure shows the summary of studies overall and subdivided by the number of bacterial species used. "multiple": combination of bacteria, "single": one bacterial species used.

The beneficial effect on fasting glucose level was significant both in the multiple strains probiotics subgroup (− 19.84 mg/dL, 95% CI − 31.45, − 8.23, *p* = 0.001) and in the single bacteria probiotic sub-group (− 16.07 mg/dL, 95% CI − 25.88, − 6.26, *p* = 0.001) with no significant difference between the two sub-groups (*p* = 0.892). If we excluded the six articles where probiotics were co-supplemented with either vitamin D or chromium or selenium, and the article where the placebo group also got yoghurt with some bacteria, the heterogeneity did not change, either (Figure [S6](#MOESM1){ref-type="media"}).

The meta-analysis of fifteen trials showed a significant reduction of fasting insulin levels by 1.40 µIU/mL (95% CI − 2.52, − 0.27, *p* = 0.015). Heterogeneity was not significant (46.8%, *p* = 0.024), sub-group analysis was therefore not conducted.

Fourteen studies reported data about systolic and diastolic blood pressures. The meta-analysis showed a significant decrease both in systolic blood pressure (− 1.79 mmHg, 95% CI − 3.09; − 0.49, *p* = 0.007, I^2^: 0.0%, *p* = 0.890) and in diastolic blood pressure (− 1.32 mmHg, 95% CI − 2.42; − 0.21, *p* = 0.019, I^2^: 0.0%, *p* = 0.838). Since heterogeneity was not significant, no sub-group analysis was performed.

Discussion {#Sec17}
==========

In the present meta-analysis, we aimed to evaluate the effects of probiotics on BMI and metabolic parameters in patients with type 2 diabetes mellitus. Data analysis showed a significant effect of probiotics in reduction of total cholesterol, triglyceride levels, CRP, HbA1c, fasting plasma glucose, fasting insulin levels and both systolic and diastolic blood pressure values. Supplementation with probiotics increased HDL levels however did not have a significant effect on BMI or LDL levels.

Such an evaluation is of high potential importance, as this patient group has especially high risk of cardiovascular diseases. It is crucial to reduce all the modifiable risk factors with efficient and multifactorial therapeutic methods and probiotic supplementation could be a complementary approach.

High total cholesterol levels, high blood pressure and type 2 diabetes mellitus are major risk factors of cardiovascular diseases. Reduction of the high total cholesterol and LDL levels in order to reduce the risk of major cardiovascular events is essential^[@CR53]^. Every 1 mmol/L increment in total cholesterol levels increases the risk of cardiovascular diseases by 20% in women and by 24% in men^[@CR54]^. Our results show that the consumption of probiotics has a decreasing effect on serum cholesterol levels. The mechanisms behind this reduction are that probiotics seem to be able to reduce serum cholesterol levels by reducing cholesterol absorption in the intestines^[@CR55]^ and by the inhibition of HMG-CoA reductase enzyme thereby inhibiting endogenous cholesterol synthesis^[@CR56]^.

The exact mechanism of action for the beneficial effects of probiotics on glycemia-related parameters is not fully elucidated. The favorable effects may be due to the immunoregulatory properties of probiotics. Cani et al. demonstrated, that metabolic endotoxemia dysregulates the inflammatory tone and triggers body weight gain and diabetes. Alterations in glucose homeostasis are associated with low-grade inflammation promoted by gut microbiota-derived lipopolysaccharide or endotoxin in mice^[@CR57]^. Therefore, lowering plasma lipopolysaccharide concentration could be a strategy for the control of metabolic diseases, such as diabetes mellitus. Naito et al. showed that oral administration of Lactobacillus casei strain to obese mice led to a better insulin resistance through decreasing plasma levels of lipopolysaccharide-binding protein, a marker of endotoxemia^[@CR58]^.

In our meta-analysis, probiotics significantly reduced total cholesterol, triglyceride levels, CRP levels, HbA1c levels, fasting plasma glucose levels, fasting insulin, and blood pressure together with the increase of the HDL levels. The observed small changes may not seem to be clinically significant, however the beneficial changes in many parameters can add up leading to a reduction in the severity of type 2 diabetes-related complications, and, as a consequence in lower mortality. The main strength of our study is that we included exclusively randomized clinical trials for evaluation and the number of the included trials were much higher than in other meta-analyses in this field. Some of our outcomes (triglyceride levels, systolic and diastolic blood pressure values) included a homogenous data set, so confounding factors are unlikely to distort our results. Waist to hip ratio was not measured in most of the articles, so that we could not pool the data.

We attempted to determine whether the observed heterogeneity in our outcomes was due to the differences in the length of treatment or in the number of probiotics used. However, according to our subgroup analyses high heterogeneity still remained unknown. We need more randomized clinical trials to be able to determine the most beneficial bacteria, the optimal dosage and treatment period. The identified significant heterogeneity is due to the significant differences between the intervention of the selected articles.

There are considerable limitations in our study. The diversified settings made it impossible to assess the effect of specific probiotic strains on the analyzed parameters. Many of the analyzed studies used probiotic mixtures or dairy products containing several probiotic strains. The data of diversity and richness of gut microbiota are absent in some of the included studies. The number of the probiotic species used in the included trials varied between the studies included in the analysis. The duration of probiotic intervention differed between the included trials. Consequently, substantial heterogeneity was observed between trials within this meta-analysis. No subgroup analysis was possible to assess which particular probiotic preparation could be the most effective to improve metabolic parameters in diabetic patients. Differences in population or differences in outcome were not considerable. The study aim was to test different cardiometabolic parameters in patients with diabetes mellitus type 2 in all included studies. However, differences in intervention were substantial, due to the fact, that different species or different probiotic combinations were used. This fact is worth to mention, because we are not able to have high quality evidence due to the very high indirectness.

In conclusion, according to our meta-analysis the administration of probiotics has a beneficial role in the management of type 2 diabetes regarding metabolic profile. We have shown a significant effect of probiotics in reducing total cholesterol, triglyceride levels, CRP, HbA1c, fasting plasma glucose, fasting insulin levels and both systolic and diastolic blood pressure values. Supplementation with probiotics increased HDL level and it did not had a significant effect on BMI or LDL levels. The practical implication of our study is that probiotic administration as a supportive intervention of type 2 diabetes could be incorporated into diabetes guidelines to beneficially modify cardiometabolic risk factors. Further studies are needed to investigate the combined effects of the different antidiabetic drugs and probiotic species.
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